Description
Created On: 2020-07-15
Record Count: 20
Primary Industries
- Drugs
- Antibody
- Disease
- Therapeutic
- Drug Discovery
- Immune
- Diagnostic
- Cancer
- Surgical
- DNA
- Assay
- cardiac
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 222550
For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.
For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,
For the Commercial License, Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.
For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.
The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.
Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).
Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.
HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin technology.
IPSCIO Record ID: 222549
For the commercial license, Licensor grant the following licenses, on an Licensee Target-by-Licensee Target basis:
– a worldwide, exclusive, non-transferable license, with the right to grant a sublicense to its Affiliates, under the Licensor Technology to immunize the Mice to make Antibodies against such Licensee Target, and
– a worldwide exclusive license under the Licensor Technology, with the right to sublicense, to make, have made, import, have imported, use, offer for sale and sell Products containing Antibodies against such Licensor Target.
Licensee shall have no right to grant sublicenses to use the Mice, but may grant sublicenses under
the Licensee Technology to the extent necessary to develop, make, have made, import, use, offer for
sale and sell Products.
Licensor Technology includes the Confidential Information and Mice, and patent rights which claims an invention which is necessary for the use of the Mice to prepare the Antibodies or to develop, produce, make, have made, import, have imported, use, offer for sale and sell the Antibodies.
The Product shall mean any composition or formulation comprising one or more Antibodies, or a portion thereof, for the diagnosis, prophylaxis or treatment of human disease.
Licensee Target shall mean an Antigen selected by Licensee for immunization of Licensors HuMAb mice to generate human antibodies directed against an Antigen, in each case, which Licensor has informed Licensee is available for licensing.
HuMAb -Mouse technology is a transgenic mouse system that creates high affinity, fully human antibodies instead of mouse antibodies. Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.
Incorporating this technology into Licensee's broad drug discovery program will significantly enhance Licensee continuing efforts to identify new drug candidates.
IPSCIO Record ID: 109479
(a) an exclusive, worldwide, non-transferable license under the Licensors Technology to use the Mice to make Antibodies, and
(b) an exclusive, worldwide license under the Licensors Technology, with the right to sublicense, to use such Antibodies to make, have made, import, have imported, use, offer for sale and sell Products.
Antibody means a human monoclonal antibody with binding affinity for an Antigen derived by Licensee or its Affiliates or Sublicensees from cells obtained from one or more of the Mice.
Product shall mean any product for the treatment of human disease containing an Antibody with affinity for CRI, or a bispecific antibody consisting of a combination of an Antibody with affinity for CRI and an Antibody to Staphylococcus aureus.
'Mice' shall mean immunizable sterile transgenic mice containing unrearranged human immunoglobulin genes.
IPSCIO Record ID: 227238
Licensor hereby grants to Licensee, a Japanese corporation, and the Majority-Owned Affiliates of Licensee, solely as needed to exercise the rights that may be granted, a paid-up, non-exclusive license and/or sublicense of its rights, as the case may be, under the Licensed Technology, without the right to grant further sublicenses, to (i) Breed the XenoMouse Animals included solely for use in the Research Field in connection with activities described in subsections (ii) and (iii) of this Section 2.1.1, (ii) immunize such XenoMouse Animals solely with those Antigens that are Permitted Antigens at the time of immunization and (iii) use the Research Program Materials and Information solely for conducting research and development work within the scope of the Research Field.
Licensor hereby grants to Licensee, and the Majority-Owned Affiliates of Licensee solely as needed to practice the rights that may be granted in accordance with this agreement, a paid-up, non-exclusive license and/or sublicense, as the case may be, of its rights in the Licensor Materials and Information and all intellectual property rights Controlled by Licensor related thereto that are not licensed to Licensee pursuant to the license in subsection (a) above, solely to the extent that the Licensor Materials and Information are necessary or useful to Licensees practice of the license granted in subsection (a) above.
Option to enter into Product License Agreement:
Licensor hereby grants to Japanese Licensee an exclusive option (an 'Option') to enter into a Product License Agreement with respect to those Permitted Antigens which have been designated as Product Antigens, as further described. Each calendar year during the term of this Agreement, Licensee may obtain up to Two (2) such Options with respect to Product Antigens, pursuant to the procedures set forth.
Product shall mean (i) with regard to the Option Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to a Product Antigen or (b) Genetic Material encoding such an Antibody, wherein in respect of each Product, said Genetic Material does not encode multiple Antibodies; and (ii) with regard to a Product License Agreement, any composition which incorporates or is derived from (a) an Antibody that binds to the Product Antigen (as defined in such Product License Agreement) or (b) Genetic Material encoding such an Antibody wherein, in respect of each Product, said Genetic Material does not encode multiple Antibodies.
Product Antigen shall mean (i) with regard to the Option Agreement, a Permitted Antigen as to which Licensee has obtained an Option, as further described in the Option Agreement; and (ii) with regard to a Product License Agreement, the Antigen described in the Product License Agreement.
Xenomouse Animals shall mean transgenic mice which are Controlled by Licensor and which contain unrearranged human immunoglobulin genes that are capable of producing human antibodies when immunized with an antigen.
XenoMouseâ„¢ is a leading technology for generating fully human antibody drugs useful in treating a wide range of diseases.
XenoMouseâ„¢ is a technology to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.
Research Field shall mean the immunization of XenoMouse Animals with Permitted Antigens, the use of materials derived or generated in whole or in part from such XenoMouse Animals that are so immunized, and the use of the XenoMouse Animals themselves, solely for the creation, identification, analysis, manufacture, research, and preclinical development of Products in the Field. For purposes of clarification, it is understood that 'immunization' of XenoMouse Animals with a Permitted Antigen includes the immunization of XenoMouse Animals with any formulation or construction of a Permitted Antigen, regardless of the three dimensional configuration of such Permitted Antigen, including, but not limited to, cell lines expressing such Permitted Antigen on their cell surface and chimeric molecules containing such Permitted Antigen; provided, however, that any research, development or use of Antibodies that bind to an excluded Antigen (other than to determine whether they bind to a Permitted Antigen) shall be outside of the scope of the licenses granted under the Option Agreement.
IPSCIO Record ID: 202852
For commercial license, Licensor shall grant an exclusive license or sublicense, as the case may be, with the right to grant sublicenses, under the Licensed Technology, to make and use Research Program Materials and Information solely to make and have made Product and to use, sell, lease, offer to sell or lease, import, export, otherwise transfer physical possession of or otherwise transfer title to Product, in the Territory for use in the Field.
Licensor has rights in certain strains of transgenic mice, XenoMouse(TM) mice, that are capable of producing human antibodies when immunized with an antigen.
'PRODUCT' shall mean any dosage or formulation of a product comprising an Antibody which binds to the Antigen.
IPSCIO Record ID: 280827
Licensor shall transfer to Licensee the XenoMouse Animals and other materials.
The executed option will provide exclusivity.
The materials include Forty ( 40) XenoMouseâ„¢ animals; 2 mg human anti- KLH antibody (generated in XenoMouse); Immunization protocol; Fusion protocol; and, ELISA protocol for screening.
The research collaboration agreement is to generate fully human antibodies to an antigen target in the field of inflammation.
IPSCIO Record ID: 222548
For the research license, Licensor grants an exclusive, non-transferable, license solely to use the Antibodies and hybridoma cell lines producing such Antibodies prepared by Licensor in connection with the Research for research and evaluation purposes.
For the commercial license option, Licensee shall have an option to obtain an exclusive, even as to Licensor, worldwide commercial license, solely to develop Antibodies for use in the development and commercialization of Products.
Licensor grants an exclusive, worldwide, non-transferable license under the Licensor Technology with the right to sublicense, to use hybridomas delivered by Licensor to Licensee to make or have made Antibodies, and, an exclusive, worldwide, non-transferable license under the Licensor Technology with the right to sublicense, to use Antibodies made in the Research to make, have made, import, have imported, use, offer for sale and sell Products.
The Product shall mean any product for the treatment or diagnosis of human disease containing an Antibody provided by Licensor or produced from any hybridoma provided by Licensor or a portion thereof.
The patents are for Licensors patent rights which claims an invention which is necessary or useful for the use of the Antibodies or the hybridoma cell lines transferred hereunder to make, use or sell Products.
The Antigens are C-proteinase/bone-morphogenic protein, M-tolloid, M-tolloid-like (1), M-tolloid-like (2), N-proteinase, Fibril assembly sequences, Connective tissue growth factor (CTGF), CTGF receptor, CTGF receptor and/or receptor conjugates which include the CTGF receptor, An alternative ligand for the CTGF receptor to be named which has not been previously licensed to a third party by Medarex, CTGF fragments, and, An alternate CTGF or CCN homolog protein fragment.
'Combining the power of the HuMAb -Mouse technology with the expertise of Licensee a fibrosis industry leader, we have created the opportunity to develop effective anti-fibrotic therapeutics, specifically targeting the unmet areas of chronic organ fibrosis and post-surgical scarring'.
Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue in a reparative or reactive process. This can be a reactive, benign, or pathological state. In response to injury, this is called scarring, and if fibrosis arises from a single cell line, this is called a fibroma.
IPSCIO Record ID: 289177
The Licensor of Scotland agrees to grant the German Licensee under the patent rights a non-exclusive world-wide licence to the extent necessary to commercialise the Deimmunised antibody and/or the deliverables in the field.
Licensor grants for each specific Deimmunised antibody a non-exclusive licence under the patent rights to the extent necessary for worldwide commercialisation of the Deimmunised antibody derived from the specific Single-Chain Antibody sequence.
Licensee is the owner of a cDNA which encodes a Single-Chain Antibody which binds to a specific antigen.
Licensor patent rights shall mean all patent applications and granted patents relevant to Deimmunization Technology.
Deimmunised antibody shall mean all genetically engineered variant(s) of the single-chain antibody arising from the research.
Deimmunization technology shall mean the technical process applied by Licensor to generate Deimmunised antibody as outlined in the research program.
DeImmunisation increases the clinical potential of antibody and protein therapeutics by eliminating/reducing the T-cell response caused when the therapeutic molecule is recognised as foreign by the patient's immune system. The technology is based on ‘peptide threading' and works by identifying potential T-cell epitopes on the therapeutic antibody or protein. T-cell epitopes are sites on the therapeutic molecule which can bind to MHC class II, triggering a T-cell mediated immune response. Once this potentially immunogenic region of the antibody is identified, it is removed from the molecule by single amino acid substitutions, thus eliminating/reducing the therapeutic antibody or protein's immunogenicity and increasing its safety. This can be done without compromise to efficacy.
IPSCIO Record ID: 209518
Licensor grants to the English Licensee, non-exclusive sublicences under the following Licensor In-Licenses pursuant to which Licensor Controls XenoMouse Lambda Animals as applicable to Antibodies that bind to and are directed against the Amendment No. 1 Antigen and that contains a lambda light chain Derived from XenoMouse Lambda Animals immunized.
XenoMouse technology involves transgenic mouse strains that possess an immune system in which the mouse antibody-producing genes have been inactivated and functionally replaced by most of the human antibody-producing genes. The XenoMouse animal's immune system still recognizes human antigens as foreign, but instead of producing mouse antibodies it produces fully human antibodies.
XenoMax(TM) technology allows researchers to rapidly scan the majority of the immune repertoire of an immunized XenoMouse animal, and to identify B-cells that produce antibodies with the desired functional properties and the optimum affinities.
IPSCIO Record ID: 256278
Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.
Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.
GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.
Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.
The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.
Companies will collaboration to identify and develop antibody-based therapeutics for the treatment of inflammatory and autoimmune diseases.
IPSCIO Record ID: 243460
(a) Make or have made Licensed Antibody Phage Display Materials;
(b) Solely for Research and Development purposes, conduct Antibody Phage Display;
(c) Make or have made Research Quantities of a Licensed Immunoglobulin;
(d) Transfer Antibody Phage Display Materials, Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Licensee Collaborator; and
( e) Use, sell, offer to sell, import and export Licensed Immunoglobulins.
Antibody Phage Display means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.
Licensed Antibody Phage Display Materials means any collection or library of polynucleotide sequences, including without limitation a Licensee Library, created by Licensee and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage, including without limitation a Licensee Library, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin and an outer surface polypeptide of a bacteriophage.
Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator through the use of Licensed Antibody Phage Display Materials.
IPSCIO Record ID: 273384
The AVP Anthrax Patents constitute all patents and patent applications owned by Sellers necessary or useful for the exploitation of the Product and the conduct of the Product Line Operations.
Licensed Product means the Product as licensed or approved by any applicable Regulatory Authority or any product Developed or Commercialized under a sublicense of the rights granted under the Asset License in this Agreement.
IPSCIO Record ID: 256276
Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.
The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.
Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.
IPSCIO Record ID: 230777
The patents are for Chimeric antibodies comprising antigen binding sites and B and T cell epitopes, and, Immunization of infants.
The right is for a proprietary immunotherapy platform technology.
IPSCIO Record ID: 291151
5,618,920 – Modular assembly of antibody genes, antibodies prepared thereby and use
5,028,530 – AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
5,846,818 – Pectate lyase signal sequence
Licensed Antibody Phage Display Materials means (i) any collection or library of polynucleotide sequences, created by and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or (ii) any collection or library of bacteriophage, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage. For the avoidance of doubt, and without expanding the definition thereof, specifically excluded from the definition of Licensed Antibody Phage Display Materials are (x) any article of manufacture or composition of matter suitable for display, expression or secretion of an Immunoglobulin in or from any organism or system other than bacteria and (y) any materials or composition of matter otherwise meeting the definition of Licensed Antibody Phage Display Materials but created by or under the control of any entity, other than Licensee, engaged in a Commercial Antibody Phage Display Business; provided, that, notwithstanding the foregoing, any materials or composition of matter otherwise meeting the definition of Licensed Antibody Phage Display Materials but created by or under the exclusive control of a Licensee Collaborator shall constitute Licensed Antibody Phage Display Materials, but only to the extent derived by such Licensee Collaborator exclusively from Licensed Antibody Phage Display Materials created by or under the exclusive control of Licensee and properly transferred by Licensee to such Licensee Collaborator in accordance with the applicable provisions of this Agreement and such Licensee Collaborator acknowledges that the transfer restrictions and other provisions hereof apply thereto.
Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator (as defined above) through the use of Licensed Antibody Phage Display Materials.
Licensed Immunoglobulin Information means any data, know-how or other information relating, concerning or pertaining to a Licensed Immunoglobulin, including, without limitation, data, know-how or other information characterizing or constituting such Licensed Immunoglobulin’s polynucleotide or amino acid sequence, purported function or utility, antigen binding affinity, or physical or biochemical property.
Immunoglobulin means any molecule, including without limitation, full immunoglobulin molecules (e.g., IgG, IgM, IgE, IgA and IgD molecules) and ScFv, Fv and Fab molecules, that has an amino acid sequence by virtue of which it specifically interacts with an antigen and wherein that amino acid sequence consists essentially of a functionally operating region of an antibody variable region including, without limitation, any naturally occurring or recombinant form of such a molecule.
Licensee Collaborator means any person or entity who is an authorized end-user of Licensed Antibody Phage Display Materials, the intended recipient of Licensed Immunoglobulins or Licensed Immunoglobulin Information transferred from Licensee and/or a person or entity on whose behalf Licensee knowingly engages in Antibody Phage Display.
Development Partner means a Third Party from whom a party either in- licenses a target for development and/or commercialization by the in-licensing party or with whom a party shares the economic risk of development or commercialization of a target or product being developed or commercialized on behalf of the applicable party.
IPSCIO Record ID: 116563
Each license shall be a nonexclusive, worldwide license under the Licensors Patent Rights to make, have made, use, import, market, promote, offer for sale and sell or otherwise dispose of Antibodies pursuant to a Licensors License Agreements. The rights of Licensee shall include the right to grant sublicenses for Antibodies in accordance with the terms of the applicable License Agreement.
The Antigens are target molecules to which an Antibody specifically binds and includes all epitopes on that target molecule.
The licensed product means an Antibody with respect to which Licensee has either significant marketing rights or has done significant development, including without limitation created, humanized or conducted preclinical or clinical development, the manufacture, import, use, offer to sell or sale of which would infringe, if not licensed under this Agreement, also known as a Valid Claim.
IPSCIO Record ID: 245920
Licensor grants an exclusive Option for each Research Antigen designated to obtain the Exclusive License set forth during the Option Period.
If Licensee elects to exercise its option to acquire an Exclusive License with respect to a particular Research Antigen, and Licensee pays the Option Exercise Fee, then subject to the terms and conditions of this Agreement, and commencing as of the date that Licensor has received the Option Exercise Fee from Licensee, Licensor is automatically deemed to grant, and in such event hereby grants, to Licensee, on a Research Antigen-by-Research Antigen basis, a worldwide, exclusive, even as to Licensor, nontransferable, royalty-bearing license under the Licensor Technology, with the right to sublicense, to discover, have discovered, to develop, have developed, make, have made, import, have imported, export, have exported, use, sell and have sold Products directed toward such Research Antigen within the Field in the Territory.
The licensors patents and technology are for Antibodies, Research Antigens, Exclusive Antigens, and Jointly-Invented Inventions Related thereto.
Antigen means any protein, including any glyco- or lipo-protein, carbohydrate, compound or other composition, and any fragment, peptide or epitope thereof, to which an antibody hinds.
Product means any and all products where the manufacture, sale or use of such products would have constituted a misappropriation of Drug Conjugation Technology, Licensor Know-How, Improvements or New Technologies, and/or an infringement of the Licensed Patents but for the licenses granted in this Agreement.
The binding of an antibody to the surface of a cancer cell rarely induces cell death by itself. Enhancing the potency of antibodies through the linkage of drug payloads provides a means to selectively kill cancer cells while limiting damage to normal tissue.
IPSCIO Record ID: 211874
Licensor further grants a non-transferable, non-exclusive, perpetual and irrevocable license under the Patent to use, sell, offer to sell, and import: CHW Antibody contained in CHW Kits; and, CHW Antibody Derivatives contained in CHW Kits.
Licensee shall have no right to sublicense.
Licensor grants Licensee an immunity from suit for licensed products.
Licensor grants an exclusive, non-transferable, sublicensable (only to Licensee partners) license, to use and display Japan Witness® trademark only for ICT lateral flow veterinary test kit products sold in Japan. With regard to this license, Licensee shall not, and shall have no right to, sell outside of Japan, or authorize its distributors, resellers, and OEMs to sell outside of Japan, ICT lateral flow veterinary test kit products bearing Japan Witness® trademark.
The biological materials are Anti-CHW MAb, clone key DI16872.5-USDA code E118.00, Rabbit Anti-CHW PAb-USDA code E019.00, Rabbit Anti-CPV PAb-USDA code E024.01, and, Anti-CPV MAb, clone key A1C2.32-USDA code E024.01.
The products are canine heartworm test kits.
IPSCIO Record ID: 230756
For the Know-how License, Licensor grants to:
– an exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is solely related to the Collaboration Inhibitor including but not limited to the non-clinical development, process development, manufacturing, clinical development, and marketing of a Collaboration Inhibitor, in pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.
– a non-exclusive worldwide license to use Licensor Know-how within the Field, wherein such Know-how is related to a Collaboration inhibitor including but not limited to the non-clinical development, and marketing of a Collaboration Inhibitor, in-pursuance of the Research & Development Plan, during the Collaboration Term, and during the remaining Term of this Agreement.
The patents include but are not limited to Methods and Compositions for the Treatment of Inflammatory Diseases; Methods and Compositions for the Treatment of glomerulonephritis and other Inflammatory Diseases; Use Of C5-Specific / Antibodies For Reducing Immune And Hemostatic Dysfunctions During Extracorporeal Circulation; Recombinant DNA Products And Methods; and, Single Polypeptide Chain Molecules.
The Collaboration Inhibitor means the humanized anti-C5 monoclonal antibody coded h5G 1.1-ScFv and analogs, derivatives and formulations thereof owned or otherwise Controlled by Licensor.
IPSCIO Record ID: 260433
The German Licensor grants to the German Licensee an exclusive license, with the right to grant sublicenses, to the Licensed Technology, other than the Sublicensed Patents and the Sublicensed Know-How, to conduct research and development, make, have made, use, Commercialize, and import the Products in the Field in the Territory.
Licensor grants an exclusive sublicense, with the right to grant further sublicenses, under the rights and licenses granted to Licensor in the Upstream Agreements with respect to the Sublicensed Technology, to research, develop, Commercialize, make, have made, use, offer for sale, sell, and import the Products in the Field in the Territory.
This agreement includes a non-exclusive grant beck from Licensee to Licensor.
GM-CSF means the whole or part and natural variants of the granulocytemacrophage colony stimulating factor (GM-CSF) identified by the SWlSS-PROT entry name CSF2 _ HUMAN and accession number P04141 with the amino acid sequence as defined.
MT203 Product means any pharmaceutical product comprising the IgG1 antibody with the variable domain amino sequence.
The patents are for Antibody neutralizers of human granulocyte macrophage colony stimulating factor; and, Method of identifying binding site domains that retain the capacity of binding to an epitope.